Neuroendocrine Tumors Therapeutics - Global Strategic Business Report

The global market for Neuroendocrine Tumors Therapeutics was estimated at US$3.5 Billion in 2023, and is projected to reach US$6.6 Billion by 2030, growing at a CAGR of 9.5% from 2023 to 2030. This comprehensive report provides an in-depth analysis of market trends, drivers, and forecasts, helping you make informed business decisions.

The growth in the neuroendocrine tumors therapeutics market is driven by several factors, including increased awareness of NETs, advancements in diagnostic methods, and the introduction of innovative treatments that target specific molecular pathways involved in tumor growth. Additionally, the rising prevalence of NETs and the aging global population contribute to the expanding demand for effective treatments. Pharmaceutical companies continue to invest in the development of more efficacious and less toxic therapeutic options, while regulatory agencies support these initiatives through accelerated approval processes for drugs that address unmet medical needs in the NET patient community.

Key Insights:

Market Growth: Understand the significant growth trajectory of the Somatostatin Analogs segment, which is expected to reach US$3.8 Billion by 2030 with a CAGR of a 8.5%. The Targeted Therapy segment is also set to grow at 11.5% CAGR over the analysis period.
Regional Analysis: Gain insights into the U.S. market, estimated at $917.4 Million in 2023, and China, forecasted to grow at an impressive 8.0% CAGR to reach $970.6 Million by 2030. Discover growth trends in other key regions, including Japan, Canada, Germany, and the Asia-Pacific.

Why You Should Buy This Report:

Detailed Market Analysis: Access a thorough analysis of the Global Neuroendocrine Tumors Therapeutics Market, covering all major geographic regions and market segments.
Competitive Insights: Get an overview of the competitive landscape, including the market presence of major players across different geographies.
Future Trends and Drivers: Understand the key trends and drivers shaping the future of the Global Neuroendocrine Tumors Therapeutics Market.
Actionable Insights: Benefit from actionable insights that can help you identify new revenue opportunities and make strategic business decisions.

Key Questions Answered:

How is the Global Neuroendocrine Tumors Therapeutics Market expected to evolve by 2030?
What are the main drivers and restraints affecting the market?
Which market segments will grow the most over the forecast period?
How will market shares for different regions and segments change by 2030?
Who are the leading players in the market, and what are their prospects?

Report Features:

Comprehensive Market Data: Independent analysis of annual sales and market forecasts in US$ Million from 2023 to 2030.
In-Depth Regional Analysis: Detailed insights into key markets, including the U.S., China, Japan, Canada, Europe, Asia-Pacific, Latin America, Middle East, and Africa.
Company Profiles: Coverage of major players such as AbbVie, Inc., Boehringer Ingelheim International GmbH, Bristol-Myers Squibb Company, and more.
Complimentary Updates: Receive free report updates for one year to keep you informed of the latest market developments.

Select Competitors (Total 86 Featured):

AbbVie, Inc.
Boehringer Ingelheim International GmbH
Bristol-Myers Squibb Company
Daiichi Sankyo Co., Ltd.
Eli Lilly and Company
Exelixis, Inc.
HUTCHMED
Ipsen Pharma
Isotopen Technologien MA¼nchen
Lantheus Holdings, Inc.
Merck & Co., Inc.
Neurocrine Biosciences, Inc.
Novartis AG
Pfizer, Inc.
Sun Pharmaceutical Industries Ltd.

I. METHODOLOGYII. EXECUTIVE SUMMARY

1. MARKET OVERVIEW

Influencer Market Insights
World Market Trajectories
Global Economic Update
Neuroendocrine Tumors Therapeutics - Global Key Competitors Percentage Market Share in 2024 (E)
Competitive Market Presence - Strong/Active/Niche/Trivial for Players Worldwide in 2024 (E)

2. FOCUS ON SELECT PLAYERS

3. MARKET TRENDS & DRIVERS

Rising Incidence and Awareness of Neuroendocrine Tumors
Advances in Molecular Diagnostics Enhancing Treatment Selection
New Developments in Targeted Radionuclide Therapies
Expanding Use of Genomic Profiling in Therapy Choices
Impact of Immuno-Oncology on NETs Treatment
Growing Importance of Multidisciplinary Care Teams
Increasing Number of FDA Approvals for Novel Therapies
Innovations in Drug Delivery Systems
Clinical Trials Addressing Unmet Needs in NET Treatment
Economic Impacts of Long-Term Cancer Treatment
Partnerships Between Biotech Firms and Academic Centers
Regulatory Support for Accelerated Drug Development
Investment Trends in Oncology Research
Demand for Personalized Medicine and Companion Diagnostics
Impact of Aging Populations on Cancer Prevalence
Challenges in Managing Chronic and Late-Stage NETs

4. GLOBAL MARKET PERSPECTIVE

Table 1: World Neuroendocrine Tumors Therapeutics Market Analysis of Annual Sales in US$ Million for Years 2014 through 2030
Table 2: World Recent Past, Current & Future Analysis for Neuroendocrine Tumors Therapeutics by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
Table 3: World Historic Review for Neuroendocrine Tumors Therapeutics by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
Table 4: World 16-Year Perspective for Neuroendocrine Tumors Therapeutics by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets for Years 2014, 2024 & 2030
Table 5: World Recent Past, Current & Future Analysis for Somatostatin Analogs by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
Table 6: World Historic Review for Somatostatin Analogs by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
Table 7: World 16-Year Perspective for Somatostatin Analogs by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2014, 2024 & 2030
Table 8: World Recent Past, Current & Future Analysis for Targeted Therapy by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
Table 9: World Historic Review for Targeted Therapy by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
Table 10: World 16-Year Perspective for Targeted Therapy by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2014, 2024 & 2030
Table 11: World Recent Past, Current & Future Analysis for Other Product Segments by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
Table 12: World Historic Review for Other Product Segments by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
Table 13: World 16-Year Perspective for Other Product Segments by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2014, 2024 & 2030
Table 14: World Recent Past, Current & Future Analysis for Hospital End-Use by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
Table 15: World Historic Review for Hospital End-Use by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
Table 16: World 16-Year Perspective for Hospital End-Use by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2014, 2024 & 2030
Table 17: World Recent Past, Current & Future Analysis for Clinics End-Use by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
Table 18: World Historic Review for Clinics End-Use by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
Table 19: World 16-Year Perspective for Clinics End-Use by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2014, 2024 & 2030
Table 20: World Recent Past, Current & Future Analysis for Other End-Uses by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
Table 21: World Historic Review for Other End-Uses by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
Table 22: World 16-Year Perspective for Other End-Uses by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2014, 2024 & 2030

III. MARKET ANALYSIS

UNITED STATES

Neuroendocrine Tumors Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United States for 2024 (E)
Table 23: USA Recent Past, Current & Future Analysis for Neuroendocrine Tumors Therapeutics by Product Segment - Somatostatin Analogs, Targeted Therapy and Other Product Segments - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
Table 24: USA Historic Review for Neuroendocrine Tumors Therapeutics by Product Segment - Somatostatin Analogs, Targeted Therapy and Other Product Segments Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
Table 25: USA 16-Year Perspective for Neuroendocrine Tumors Therapeutics by Product Segment - Percentage Breakdown of Value Sales for Somatostatin Analogs, Targeted Therapy and Other Product Segments for the Years 2014, 2024 & 2030
Table 26: USA Recent Past, Current & Future Analysis for Neuroendocrine Tumors Therapeutics by End-Use - Hospital End-Use, Clinics End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
Table 27: USA Historic Review for Neuroendocrine Tumors Therapeutics by End-Use - Hospital End-Use, Clinics End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
Table 28: USA 16-Year Perspective for Neuroendocrine Tumors Therapeutics by End-Use - Percentage Breakdown of Value Sales for Hospital End-Use, Clinics End-Use and Other End-Uses for the Years 2014, 2024 & 2030

CANADA

Table 29: Canada Recent Past, Current & Future Analysis for Neuroendocrine Tumors Therapeutics by Product Segment - Somatostatin Analogs, Targeted Therapy and Other Product Segments - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
Table 30: Canada Historic Review for Neuroendocrine Tumors Therapeutics by Product Segment - Somatostatin Analogs, Targeted Therapy and Other Product Segments Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
Table 31: Canada 16-Year Perspective for Neuroendocrine Tumors Therapeutics by Product Segment - Percentage Breakdown of Value Sales for Somatostatin Analogs, Targeted Therapy and Other Product Segments for the Years 2014, 2024 & 2030
Table 32: Canada Recent Past, Current & Future Analysis for Neuroendocrine Tumors Therapeutics by End-Use - Hospital End-Use, Clinics End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
Table 33: Canada Historic Review for Neuroendocrine Tumors Therapeutics by End-Use - Hospital End-Use, Clinics End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
Table 34: Canada 16-Year Perspective for Neuroendocrine Tumors Therapeutics by End-Use - Percentage Breakdown of Value Sales for Hospital End-Use, Clinics End-Use and Other End-Uses for the Years 2014, 2024 & 2030

JAPAN

Neuroendocrine Tumors Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Japan for 2024 (E)
Table 35: Japan Recent Past, Current & Future Analysis for Neuroendocrine Tumors Therapeutics by Product Segment - Somatostatin Analogs, Targeted Therapy and Other Product Segments - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
Table 36: Japan Historic Review for Neuroendocrine Tumors Therapeutics by Product Segment - Somatostatin Analogs, Targeted Therapy and Other Product Segments Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
Table 37: Japan 16-Year Perspective for Neuroendocrine Tumors Therapeutics by Product Segment - Percentage Breakdown of Value Sales for Somatostatin Analogs, Targeted Therapy and Other Product Segments for the Years 2014, 2024 & 2030
Table 38: Japan Recent Past, Current & Future Analysis for Neuroendocrine Tumors Therapeutics by End-Use - Hospital End-Use, Clinics End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
Table 39: Japan Historic Review for Neuroendocrine Tumors Therapeutics by End-Use - Hospital End-Use, Clinics End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
Table 40: Japan 16-Year Perspective for Neuroendocrine Tumors Therapeutics by End-Use - Percentage Breakdown of Value Sales for Hospital End-Use, Clinics End-Use and Other End-Uses for the Years 2014, 2024 & 2030

CHINA

Neuroendocrine Tumors Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in China for 2024 (E)
Table 41: China Recent Past, Current & Future Analysis for Neuroendocrine Tumors Therapeutics by Product Segment - Somatostatin Analogs, Targeted Therapy and Other Product Segments - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
Table 42: China Historic Review for Neuroendocrine Tumors Therapeutics by Product Segment - Somatostatin Analogs, Targeted Therapy and Other Product Segments Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
Table 43: China 16-Year Perspective for Neuroendocrine Tumors Therapeutics by Product Segment - Percentage Breakdown of Value Sales for Somatostatin Analogs, Targeted Therapy and Other Product Segments for the Years 2014, 2024 & 2030
Table 44: China Recent Past, Current & Future Analysis for Neuroendocrine Tumors Therapeutics by End-Use - Hospital End-Use, Clinics End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
Table 45: China Historic Review for Neuroendocrine Tumors Therapeutics by End-Use - Hospital End-Use, Clinics End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
Table 46: China 16-Year Perspective for Neuroendocrine Tumors Therapeutics by End-Use - Percentage Breakdown of Value Sales for Hospital End-Use, Clinics End-Use and Other End-Uses for the Years 2014, 2024 & 2030

EUROPE

Neuroendocrine Tumors Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Europe for 2024 (E)
Table 47: Europe Recent Past, Current & Future Analysis for Neuroendocrine Tumors Therapeutics by Geographic Region - France, Germany, Italy, UK and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
Table 48: Europe Historic Review for Neuroendocrine Tumors Therapeutics by Geographic Region - France, Germany, Italy, UK and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
Table 49: Europe 16-Year Perspective for Neuroendocrine Tumors Therapeutics by Geographic Region - Percentage Breakdown of Value Sales for France, Germany, Italy, UK and Rest of Europe Markets for Years 2014, 2024 & 2030
Table 50: Europe Recent Past, Current & Future Analysis for Neuroendocrine Tumors Therapeutics by Product Segment - Somatostatin Analogs, Targeted Therapy and Other Product Segments - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
Table 51: Europe Historic Review for Neuroendocrine Tumors Therapeutics by Product Segment - Somatostatin Analogs, Targeted Therapy and Other Product Segments Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
Table 52: Europe 16-Year Perspective for Neuroendocrine Tumors Therapeutics by Product Segment - Percentage Breakdown of Value Sales for Somatostatin Analogs, Targeted Therapy and Other Product Segments for the Years 2014, 2024 & 2030
Table 53: Europe Recent Past, Current & Future Analysis for Neuroendocrine Tumors Therapeutics by End-Use - Hospital End-Use, Clinics End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
Table 54: Europe Historic Review for Neuroendocrine Tumors Therapeutics by End-Use - Hospital End-Use, Clinics End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
Table 55: Europe 16-Year Perspective for Neuroendocrine Tumors Therapeutics by End-Use - Percentage Breakdown of Value Sales for Hospital End-Use, Clinics End-Use and Other End-Uses for the Years 2014, 2024 & 2030

FRANCE

Neuroendocrine Tumors Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in France for 2024 (E)
Table 56: France Recent Past, Current & Future Analysis for Neuroendocrine Tumors Therapeutics by Product Segment - Somatostatin Analogs, Targeted Therapy and Other Product Segments - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
Table 57: France Historic Review for Neuroendocrine Tumors Therapeutics by Product Segment - Somatostatin Analogs, Targeted Therapy and Other Product Segments Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
Table 58: France 16-Year Perspective for Neuroendocrine Tumors Therapeutics by Product Segment - Percentage Breakdown of Value Sales for Somatostatin Analogs, Targeted Therapy and Other Product Segments for the Years 2014, 2024 & 2030
Table 59: France Recent Past, Current & Future Analysis for Neuroendocrine Tumors Therapeutics by End-Use - Hospital End-Use, Clinics End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
Table 60: France Historic Review for Neuroendocrine Tumors Therapeutics by End-Use - Hospital End-Use, Clinics End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
Table 61: France 16-Year Perspective for Neuroendocrine Tumors Therapeutics by End-Use - Percentage Breakdown of Value Sales for Hospital End-Use, Clinics End-Use and Other End-Uses for the Years 2014, 2024 & 2030

GERMANY

Neuroendocrine Tumors Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Germany for 2024 (E)
Table 62: Germany Recent Past, Current & Future Analysis for Neuroendocrine Tumors Therapeutics by Product Segment - Somatostatin Analogs, Targeted Therapy and Other Product Segments - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
Table 63: Germany Historic Review for Neuroendocrine Tumors Therapeutics by Product Segment - Somatostatin Analogs, Targeted Therapy and Other Product Segments Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
Table 64: Germany 16-Year Perspective for Neuroendocrine Tumors Therapeutics by Product Segment - Percentage Breakdown of Value Sales for Somatostatin Analogs, Targeted Therapy and Other Product Segments for the Years 2014, 2024 & 2030
Table 65: Germany Recent Past, Current & Future Analysis for Neuroendocrine Tumors Therapeutics by End-Use - Hospital End-Use, Clinics End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
Table 66: Germany Historic Review for Neuroendocrine Tumors Therapeutics by End-Use - Hospital End-Use, Clinics End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
Table 67: Germany 16-Year Perspective for Neuroendocrine Tumors Therapeutics by End-Use - Percentage Breakdown of Value Sales for Hospital End-Use, Clinics End-Use and Other End-Uses for the Years 2014, 2024 & 2030

ITALY

Table 68: Italy Recent Past, Current & Future Analysis for Neuroendocrine Tumors Therapeutics by Product Segment - Somatostatin Analogs, Targeted Therapy and Other Product Segments - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
Table 69: Italy Historic Review for Neuroendocrine Tumors Therapeutics by Product Segment - Somatostatin Analogs, Targeted Therapy and Other Product Segments Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
Table 70: Italy 16-Year Perspective for Neuroendocrine Tumors Therapeutics by Product Segment - Percentage Breakdown of Value Sales for Somatostatin Analogs, Targeted Therapy and Other Product Segments for the Years 2014, 2024 & 2030
Table 71: Italy Recent Past, Current & Future Analysis for Neuroendocrine Tumors Therapeutics by End-Use - Hospital End-Use, Clinics End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
Table 72: Italy Historic Review for Neuroendocrine Tumors Therapeutics by End-Use - Hospital End-Use, Clinics End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
Table 73: Italy 16-Year Perspective for Neuroendocrine Tumors Therapeutics by End-Use - Percentage Breakdown of Value Sales for Hospital End-Use, Clinics End-Use and Other End-Uses for the Years 2014, 2024 & 2030

UNITED KINGDOM

Neuroendocrine Tumors Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United Kingdom for 2024 (E)
Table 74: UK Recent Past, Current & Future Analysis for Neuroendocrine Tumors Therapeutics by Product Segment - Somatostatin Analogs, Targeted Therapy and Other Product Segments - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
Table 75: UK Historic Review for Neuroendocrine Tumors Therapeutics by Product Segment - Somatostatin Analogs, Targeted Therapy and Other Product Segments Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
Table 76: UK 16-Year Perspective for Neuroendocrine Tumors Therapeutics by Product Segment - Percentage Breakdown of Value Sales for Somatostatin Analogs, Targeted Therapy and Other Product Segments for the Years 2014, 2024 & 2030
Table 77: UK Recent Past, Current & Future Analysis for Neuroendocrine Tumors Therapeutics by End-Use - Hospital End-Use, Clinics End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
Table 78: UK Historic Review for Neuroendocrine Tumors Therapeutics by End-Use - Hospital End-Use, Clinics End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
Table 79: UK 16-Year Perspective for Neuroendocrine Tumors Therapeutics by End-Use - Percentage Breakdown of Value Sales for Hospital End-Use, Clinics End-Use and Other End-Uses for the Years 2014, 2024 & 2030

REST OF EUROPE

Table 80: Rest of Europe Recent Past, Current & Future Analysis for Neuroendocrine Tumors Therapeutics by Product Segment - Somatostatin Analogs, Targeted Therapy and Other Product Segments - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
Table 81: Rest of Europe Historic Review for Neuroendocrine Tumors Therapeutics by Product Segment - Somatostatin Analogs, Targeted Therapy and Other Product Segments Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
Table 82: Rest of Europe 16-Year Perspective for Neuroendocrine Tumors Therapeutics by Product Segment - Percentage Breakdown of Value Sales for Somatostatin Analogs, Targeted Therapy and Other Product Segments for the Years 2014, 2024 & 2030
Table 83: Rest of Europe Recent Past, Current & Future Analysis for Neuroendocrine Tumors Therapeutics by End-Use - Hospital End-Use, Clinics End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
Table 84: Rest of Europe Historic Review for Neuroendocrine Tumors Therapeutics by End-Use - Hospital End-Use, Clinics End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
Table 85: Rest of Europe 16-Year Perspective for Neuroendocrine Tumors Therapeutics by End-Use - Percentage Breakdown of Value Sales for Hospital End-Use, Clinics End-Use and Other End-Uses for the Years 2014, 2024 & 2030

ASIA-PACIFIC

Neuroendocrine Tumors Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Asia-Pacific for 2024 (E)
Table 86: Asia-Pacific Recent Past, Current & Future Analysis for Neuroendocrine Tumors Therapeutics by Product Segment - Somatostatin Analogs, Targeted Therapy and Other Product Segments - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
Table 87: Asia-Pacific Historic Review for Neuroendocrine Tumors Therapeutics by Product Segment - Somatostatin Analogs, Targeted Therapy and Other Product Segments Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
Table 88: Asia-Pacific 16-Year Perspective for Neuroendocrine Tumors Therapeutics by Product Segment - Percentage Breakdown of Value Sales for Somatostatin Analogs, Targeted Therapy and Other Product Segments for the Years 2014, 2024 & 2030
Table 89: Asia-Pacific Recent Past, Current & Future Analysis for Neuroendocrine Tumors Therapeutics by End-Use - Hospital End-Use, Clinics End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
Table 90: Asia-Pacific Historic Review for Neuroendocrine Tumors Therapeutics by End-Use - Hospital End-Use, Clinics End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
Table 91: Asia-Pacific 16-Year Perspective for Neuroendocrine Tumors Therapeutics by End-Use - Percentage Breakdown of Value Sales for Hospital End-Use, Clinics End-Use and Other End-Uses for the Years 2014, 2024 & 2030

REST OF WORLD

Table 92: Rest of World Recent Past, Current & Future Analysis for Neuroendocrine Tumors Therapeutics by Product Segment - Somatostatin Analogs, Targeted Therapy and Other Product Segments - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
Table 93: Rest of World Historic Review for Neuroendocrine Tumors Therapeutics by Product Segment - Somatostatin Analogs, Targeted Therapy and Other Product Segments Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
Table 94: Rest of World 16-Year Perspective for Neuroendocrine Tumors Therapeutics by Product Segment - Percentage Breakdown of Value Sales for Somatostatin Analogs, Targeted Therapy and Other Product Segments for the Years 2014, 2024 & 2030
Table 95: Rest of World Recent Past, Current & Future Analysis for Neuroendocrine Tumors Therapeutics by End-Use - Hospital End-Use, Clinics End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
Table 96: Rest of World Historic Review for Neuroendocrine Tumors Therapeutics by End-Use - Hospital End-Use, Clinics End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
Table 97: Rest of World 16-Year Perspective for Neuroendocrine Tumors Therapeutics by End-Use - Percentage Breakdown of Value Sales for Hospital End-Use, Clinics End-Use and Other End-Uses for the Years 2014, 2024 & 2030

IV. COMPETITION

Companies Mentioned

AbbVie, Inc.
Boehringer Ingelheim International GmbH
Bristol-Myers Squibb Company
Daiichi Sankyo Co., Ltd.
Eli Lilly and Company
Exelixis, Inc.
HUTCHMED
Ipsen Pharma
Isotopen Technologien MA¼nchen
Lantheus Holdings, Inc.
Merck & Co., Inc.
Neurocrine Biosciences, Inc.
Novartis AG
Pfizer, Inc.
Sun Pharmaceutical Industries Ltd.

Table Information

Report Attribute	Details
No. of Pages	171
Published	November 2024
Forecast Period	2023 - 2030
Estimated Market Value ( USD ) in 2023	$ 3.5 Billion
Forecasted Market Value ( USD ) by 2030	$ 6.6 Billion
Compound Annual Growth Rate	9.5%
Regions Covered	Global
No. of Companies Mentioned	15

License	Format	Properties	Price
SINGLE USER LICENSE PDF	The product is a PDF.	This is a single user license, allowing one user access to the product.	€5471EUR$5,600USD£4,568GBP
1 - 10 USER LICENSE PDF	The product is a PDF.	This is a 1-10 user license, allowing up to ten users have access to the product.	€10396EUR$10,640USD£8,679GBP
ENTERPRISE LICENSE PDF	The product is a PDF.	This is an enterprise license, allowing all employees within your organization access to the product.	€16414EUR$16,800USD£13,703GBP

Key Insights:

Why You Should Buy This Report:

Key Questions Answered:

Report Features:

Select Competitors (Total 86 Featured):

Table of Contents

Companies Mentioned

Table Information

Related Topics

Related Reports

Neuroendocrine Tumor Treatment Market Report: Trends, Forecast and Competitive Analysis to 2030

Neuroendocrine Tumors (NETs) Market (2024 Edition): Analysis By Therapy (Somatostatin Analogs (SSAs), Targeted Therapy, Others), By Route of Administration, By Indication, By End User, By Region: Market Insights and Forecast (2020-2030)

Neuroendocrine Tumor Treatment Global Market Report 2024

Neuroendocrine Carcinoma Market Report and Forecast 2024-2032

Gastro Esophageal Junction Neuroendocrine Tumor Market: Epidemiology, Industry Trends, Share, Size, Growth, Opportunity, and Forecast 2024-2034